

## IMMUNOHISTOCHEMICAL EVALUATION OF THE EUPHORBIA INARTICULATA EXTRACT ON LIVER AND KIDNEY TISSUES IN HEPATOCELLULAR CARCINOMA RATS

Ghalia Hussine Almalki<sup>1\*</sup>, Samar Rabah<sup>2</sup>, Nadia Mohamed Said Arafa<sup>3</sup>, Safia Mohammed Bahshwan<sup>4</sup>

1. Department of Biology, Faculty of Science, Jazan University, Jazan, Saudi Arabia.
2. Department of Biology, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
3. Department of Physiology, National Organization for Drug Control and Research, Egypt.
4. Department Biology, AL-Baha University, Al-Makhwah, Saudi Arabia.

### ARTICLE INFO

#### Received:

22 Dec 2021

#### Received in revised form:

18 Mar 2022

#### Accepted:

25 Mar 2022

#### Available online:

28 Apr 2022

**Keywords:** Euphorbia inarticulate Schweinf, Antiapoptotic activity, Hepatocellular Carcinoma, Protein expression

### ABSTRACT

The study aimed to evaluation of immunohistochemical the Euphorbia Inarticulata Extract on Liver and Kidney Tissues in Hepatocellular Carcinoma Rats. Rats were grouped into six each of six as (1) control received one dose (1 ml 0.9% NaCl/ip) and two weeks after 2 weeks later received olive oil (1 ml/sc) (once/week) for 16 weeks, in line with 1% DMSO/p.o. for 18 weeks. (2) 250mg Extract and (3) 400mg Extract groups were received as in the control group and received daily extract (250 mg/kg/P.o.) and (400 mg/kg/P.o.) in DMSO for 18 weeks, respectively. (4) DENA/CCl4 group received one dose of DENA (200 mg/kg/ip) in saline and two after 2 weeks later received (3 ml/kg CCl4/sc) in olive oil (once/week) for 16 sixteen weeks, in line with 1% DMSO/p.o. for 18 weeks. DENA/CCl4 rat model group showed an induced strong positive reaction to Bax immunostaining in the cytoplasm of liver cells and glomeruli and renal tubules. The study suggests that the present model showed hepatic and renal apoptosis that is related to impairing their function and oral administration of E. inarticulata methanol extract, especially in higher dose (400 mg).

Copyright © 2013 - All Rights Reserved - Pharmacophore

**To Cite This Article:** Almalki GH, Rabah S, Arafa NMS, Bahshwan SM. Immunohistochemical Evaluation of the Euphorbia Inarticulata Extract on Liver and Kidney Tissues in Hepatocellular Carcinoma Rats. Pharmacophore. 2022;13(2):33-40. <https://doi.org/10.51847/6uBG08B9tk>

### Introduction

Hepatocellular carcinoma (HCC) is among the major primary liver cancer as well as leading source of cancer-related mortality globally [1]. Notably, HCC usually becomes apparent in individuals who have underlying chronic liver disease and cirrhosis that might be caused by viral infections (i.e. hepatitis B & C viruses) [2]. Other risk factors for HCC include environmental toxins, oxidative stress, autoimmune hepatitis, obesity, chronic alcohol use, diabetes mellitus, etc [3, 4]. In Saudi Arabia, liver cancer represents 6.3% of all cancers, with hepatocellular carcinoma accounting for about 90% of all liver cancers [5, 6].

Euphorbiaceae (the spurge family) is a large flowering plant family that comprises about 300 genera and 8,000 species throughout the world, particularly in the arid and semi-arid regions of the tropics and subtropics. *Euphorbia* is the biggest genus of the *Euphorbiaceae* plant family, consisting of close 2 thousand species [7]. The family is highly ecologically diverse; represented by the trees, shrubs, herbs, and even lianas, and described by the occurrence of either white milky latex (such as *Euphorbia*) or watery sap (such as *Ricinus* and *Chrozophora*) which are irritating and more or less toxic and usually protects these plants from browsing animals [8, 9].

Previous surveys in Saudi Arabia showed that a large number of Saudi people are interested in using alternative medicine either alone or along with modern medications [10-12]. The most common medicinal plants found in the region belong to the *Leguminosae*, *Labiatae*, *Compositae*, and *Euphorbiaceae* [13]. *Euphorbiaceae* is widely distributed throughout Saudi Arabia, with about 40 species have been recognized [14, 15]. *Euphorbia inarticulata* Schweinf (**Figure 1**) is a branched spiny, between 1–2 m high, 3–5-angled succulent, yellow cyathia clustered at the top of the stem, with 3-10 mm long, paired spines [7, 14]. It is common in scattered localities in the southwestern region of Saudi Arabia [16]. Overall, studies on *E. inarticulata* Schweinf

**Corresponding Author:** Ghaliahussine Almalki; Department of Biology, Faculty of Science, Jazan University, Jazan, Saudi Arabia. E-mail: g.almalki@gmail.com.

are very limited. A previous study revealed that topical use of ethyl acetate extract of *E. inarticulata* on experimentally induced excision injuries in rats presented significant results of wound shrinkage and healing with higher fibroblasts and collagen content in treated animals compared to standard drug-treated groups and control [17]. Nonetheless, the methanol extracts of *E. inarticulata* Schweinf showed no antileishmanial activity [18]. However, studies on the activity of *E. inarticulata* are rare-existent in the literature. Owing to this, the present *in vivo* study aimed to explore the antiapoptotic action of the *E. inarticulata* Schweinf methanolic extract oral supplementation on HCC induced by DENA and CCl<sub>4</sub> in male Wistar rats through the immunohistochemical changes in expressions of Bax immunostaining in liver and kidney tissues.

## Materials and Methods

### *Plant Material Collection*

The present study collected *Euphorbia inarticulata* Schweinf. (March 2017, 2018) from Al'Aridah, Jazan region, Saudi Arabia 17°03'45.6"N 43°03'03.7"E <https://goo.gl/maps/cXT6m1ppRSo> and Photograph from the collection area of the *Euphorbia inarticulata* Schweinf. Identification of the plant material was kindly verified by Dr. Yahya Masrahi, Department of Biology, Faculty of Science, Jazan University, Saudi Arabia.

### *Extraction*

The dried *Euphorbia* whole plant (150 gm) was ground and extracted as previously described by Wang *et al.*, (2012) with hexane for 24 hours and then filtered. The residue was extracted by soaking in ethyl acetate for 24 hours and then filtered [19]. The collected residue was extracted by soaking in methanol for 24 hours then filtered and the filtrate was concentrated by a rotary evaporator (BÜCHI, Switzerland). The dried methanol extract was weighed to be used in the study.

### *Experimental Animals*

Thirty-six adult male Wistar rats weigh up to 140-160 g were employed in the current research. Animals were kept under a controlled temperature of 25±2 °C and 12 hours of light/dark cycle throughout the experiment. The animals were free to use water and a standard commercial pelleted diet. Every effort was made to reduce the number and distress of animals and all animal procedures followed the recommendations of the Institutional Review Board for Scientific Research- Jazan University (Saudi Arabia) with reference No. REC41/1/071.

### *Hepatocellular Carcinoma Induction*

For the induction of hepatocellular carcinoma, rats were given a single intraperitoneal dose of DENA (200 mg/kg) dissolved in saline. After two weeks, the animals received subcutaneous injections of carbon tetrachloride (CCl<sub>4</sub>) (3 ml/kg) dissolved in olive oil once weekly for 16 weeks to promote the carcinogenic effect of DENA [20].

### *Experimental Design*

The experimental animals were randomly designated into 6 groups of 6 rats respectively as follows:

**Group 1: Control**, rats were administered 1 dose of 1ml intraperitoneal injection of 0.9% NaCl. after 2 weeks, the animals received 1 ml olive oil hypodermically (once/week) for sixteen weeks. Furthermore, the rats were administered 1% DMSO via oral gavage daily for 18 weeks.

**Group 2: 250 mg Extract**, rats received NaCl and olive oil as Group I. Then, the animals received 250 mg/kg methanol extract daily dissolved in DMSO via oral gavage for 18 weeks (low dose normal group).

**Group 3: 400 mg Extract**, rats received NaCl and olive oil as Group I. Then, the animals received 400 mg/kg methanol extract daily dissolved in DMSO via oral gavage for eighteens weeks (high dose normal group).

**Group 4: DENA/CCl<sub>4</sub>**, rats received an intraperitoneal injection of DENA (200 mg / kg) dissolved in 0.9% NaCl. Two weeks later, the animals received 3 ml / kg of CCl<sub>4</sub> diluted with olive oil subcutaneously **once a week** for 16 weeks. In addition, rats received 0.1% DMSO daily for 18 weeks **by gavage** (hepatocellular carcinoma rat model group).

**Group 5: DENA/CCl<sub>4</sub> + 250 mg/kg Extract**, rats received DENA and CCl<sub>4</sub> as a group (4) and 250 mg/kg extract daily for eighteen weeks (treated group, low dose).

**Group 6: DENA/CCl<sub>4</sub> + 400 mg/kg Extract**, rats received DENA and CCl<sub>4</sub> as Group (4) and 400 mg/kg extract daily for 18 weeks (treated group, high dose).

Body weights of all animals were measured every week to adjust the doses of the methanolic plant extract and CCl<sub>4</sub> for every kg of body weight over the entire period of the experiment as indicated by any change in the body.

### *Tissue Sampling*


At the end of the experiment, rats were fasted overnight, but were given free water intake and then sacrificed with diethyl ether under mild anesthesia. Liver and kidney tissues were rapidly excised, and specimens of liver and kidney tissues were secured in ten percent neutral buffered formalin solution for the immunohistochemical staining.

### *Immunohistochemical Staining for Bax and Bcl-2*

The liver and kidney tissues of control and experimental animals used to locate cells expressing bcl2 and Bax proteins were dependent on immunohistochemistry. based on a streptavidin-biotin peroxidase method (Biogenex, San Ramon, CA, USA) [21]. Tissues from every group were secured in buffered formalin (10%), set in paraffin, cut sections (4  $\mu\text{m}$ ) with the use of a rotary microtome. It was then located on poly-L-lysine coated clean glass slides, dried at 37°C and used for immunohistochemical studies. Tissue sections embedded in paraffin were deparaffinized and rehydrated with stepwise ethanol diluted with distilled water. Incubation with hydrogen peroxide (3%) blocked Endogenous peroxidase in methanol for 10 min. Microwave helped achieve antigen retrieval in citrate buffer solution (pH 6.0) for 10 minutes, followed by a washing step with Tris-buffered saline (pH 7.6). The tissue sections were then incubated with power Block TM reagent (BioGenex, San Ramon, CA, USA), universal proteinaceous blocking reagent, for 15 min at room temperature to block non-specific binding. Then, these tissue sections were incubated with specific primary antibodies (Bax and Bcl-2, Thermo Scientific, USA) overnight at 4°C. The bound primary antibody was incubated with the secondary antibody conjugated with horseradish peroxidase for 30 min at room temperature. The antigen-antibody complex was detected using 3, 3'-diaminobenzidine (Sigma Fast DAB tablets, D-4293, Sigma St. Louis, MO, USA) and was used as a chromogen after rinsing with Tris-buffered saline. Only cytoplasmic staining was considered for evaluation while nuclear staining was interpreted to be nonspecific staining. The intensity of the staining was scored in ascending order from negligible < mild < moderate < strong intensity staining pattern [22].


## Results and Discussion

### *Effect of E. Inarticulata Methanol Extract on Liver Bax and Bcl-2 Protein*



**Figure 1.** Photomicrographs of liver sections of rats from the control group (a), 250 mg euphorbia (b), and 400 mg euphorbia (c) treated groups, respectively showing negligible Bax immunostaining. A photomicrograph from DENA/CCl4 shows induced Bax immunostaining in the cytoplasm of liver cells (d). A photomicrograph from DENA/CCl4 treated with 250 mg euphorbia showed mild expression of Bax (e) and a photomicrograph from DENA/CCl4 treated with 400 mg euphorbia showed moderate expression of Bax X (f).


Results of liver tissue of Bax protein immunostaining are represented in **Figure 1**. Where the photomicrograph of the normal control group showed negligible Bax immunostaining (a), and in the same manner photomicrographs of the 250mg Extract group (b) and the 400mg Extract group (c) liver sections showed negligible Bax immunostaining. Meanwhile, the photomicrograph of the HCC rat model group (DENA/CCl4) showed a strong positive reaction to Bax immunostaining in the cytoplasm of liver cells (d). Treatment with the *E. inarticulata* methanol extract recorded in photomicrograph (e) that the low dose of 250mg presented a minimal expression of Bax in the cytoplasm of hepatocytes, while the high dose of 400mg presented moderate expression of Bax in the cytoplasm of hepatocytes (f).



**Figure 2.** Photomicrographs of liver sections of rats from the control group (a), 250 mg euphorbia (b), and 400 mg (c) euphorbia treated groups, respectively showing a positive reaction to Bcl-2 antibodies mainly in the cytoplasm of hepatocytes. A photomicrograph from DENA/CCl4 rats showed a faint cytoplasmic reaction to Bcl-2 antibodies (d). A photomicrograph from DENA/CCl4 rats treated with 250 mg euphorbia showed moderate expression of Bcl-2 (e) and a photomicrograph from DENA/CCl4 rats treated with 400 mg euphorbia showed mild expression of Bcl-2 (f).


Results of liver tissue immunostaining of Bcl-2 protein are represented in **Figure 2**. The photomicrograph of the normal control group showed a positive reaction to Bcl-2 antibodies mainly in the cytoplasm of hepatocytes (a), as well as in photomicrographs of the 250mg Extract group (b) and the 400mg Extract group (c). However, the liver section of the DENA/CCl4 group showed a faint cytoplasmic reaction to Bcl-2 antibodies (d). Treatment with the *E. inarticulata* methanol extract (e) by the low dose of 250mg showed moderate expression of Bcl-2 in the cytoplasm of hepatocytes, while the high dose of 400mg showed mild expression of Bcl-2 in the cytoplasm of hepatocytes (f).

*Effect of E. Inarticulata Methanol Extract on Kidney Bax and Bcl-2 Protein*



**Figure 3.** Photomicrographs of kidney sections of rats from the control group (a), 250 mg euphorbia (b), and 400 mg (c) euphorbia treated groups, respectively showing negligible Bax immunostaining. A photomicrograph from DENA/CCl4 treated rats showed a strong positive reaction to Bax in glomeruli and renal tubules (d). A photomicrograph from DENA/CCl4 treated with 250 mg euphorbia showed mild expression of Bax in glomeruli (e) a photomicrograph from DENA/CCl4 treated with 400 mg euphorbia showed moderate expression of Bax in glomeruli and renal tubules (f).

Results of kidney tissue immunostaining of Bax protein are represented in **Figure 3**. Where the photomicrograph of the normal control group showed negligible Bax immunostaining (a), like the already represented in the photomicrographs of the 250mg Extract group (b) and the 400mg Extract group (c). In the meantime, the photomicrograph of the HCC rat model group (DENA/CCl4) showed a strong positive reaction to Bax immunostaining in the glomeruli and renal tubules (d). Treatment with the *E. inarticulata* methanol extract recorded in photomicrograph (e) that the low dose of 250mg showed mild expression of Bax in glomeruli, while the high dose of 400mg showed moderate expression of Bax in the glomeruli and renal tubules (f).



**Figure 4.** Photomicrographs of kidney sections of rats from the control group (a), 250 mg euphorbia (b), and 400 mg euphorbia (c) treated groups, respectively showing strong Bcl-2 immunostaining in glomeruli and renal tubules. A photomicrograph from DENA/CCl4 rats showed negligible reaction to Bcl-2 immunostaining (d). A photomicrograph from DENA/CCl4 rats treated with 250 mg euphorbia showed strong expression of Bcl-2 in glomeruli and renal tubules (e) and a photomicrograph from DENA/CCl4 rats treated with 400 mg euphorbia showed moderate expression of Bcl-2 in glomeruli and renal tubules (f).

Results of kidney tissue immunostaining of Bcl-2 protein are represented in **Figure 4**. The photomicrographs showed strong Bcl-2 immunostaining in glomeruli and renal tubules in the normal control group (a), the low dose (250mg) Extract group (b), and the high dose one (400mg) (c). However, DENA/CCl4 group showed negligible cytoplasmic reaction to Bcl-2 antibodies (d). Treatment with the *E. inarticulata* methanol extract (e) by the low dose of 250mg showed strong expression of Bcl-2 in glomeruli and renal tubules. Moreover, the high dose group (400mg) presented moderate expression of Bcl-2 in glomeruli and renal tubules (f).

The present study is the first to provide information on the anti-apoptotic activity of *E. inarticulata* Schweinf extract on DENA/CCl4-induced HCC in rats. Many herbal products have been investigated by *in vitro* and *in vivo* as anti-HCC agents for many years, and certain natural products were found productive in the co-treatment and inhibition of HCC [23]. Hence, effective herbal products have been recommended to be used along with previous chemical drugs and following stoppage of chemical drugs, as a conservational remedy to prevent HCC development [24].

Diethylnitrosamine (DENA) is a notorious chemical with a strong hepatocarcinogenic effect, used to induce HCC in experimental rat models and is similar to human HCC [25]. Also, liver fibrosis was induced in rats by subcutaneous injection of CCl4 which is largely used as a toxic solvent for making animal models of liver fibrosis/cirrhosis [26]. In addition, the hepatorenal toxicity including cell apoptotic induction already been demonstrated in many studies which recorded previously structural integrity of liver and kidney tissues damaged by DENA and CCl4 [27-32]. It was previously concluded that injection of DENA and then repeated prescription of carbon tetrachloride CCl4 could be employed as a model for studying the molecular mechanisms of fibrogenesis and HCC growth and in cancer hazard/chemotherapy testing of drug candidates [33]. The present study results revealed a strong positive reaction to Bax immunostaining and a faint cytoplasmic reaction to Bcl-2 antibodies in the cytoplasm of liver cells which indicates the hepatocyte apoptosis in the rat model is in line with the previously reported in different studies. A previous study used a rat model of HCC induced by DENA recorded increased cytoplasmic staining for Bcl-2 with subsequently decreased cytoplasmic staining for Bax [34], and recently, CCl4 administration was recorded to cause upregulation of pro-apoptotic protein Bax and downregulation of antiapoptotic protein Bcl-2 [26]. It was postulated later that the mitochondrial signaling pathway might be involved in CCl4-induced hepatocyte apoptosis through upregulating Bax and downregulating Bcl2 [35]. The results of the present study revealed that *E. inarticulata* methanolic extract supplementation recorded negligible Bax immunostaining and positive reaction to Bcl-2 antibodies mainly in the cytoplasm of hepatocytes as

well as in glomeruli and renal tubules. That's in the low (250mg) and high (400mg) doses without any significant change as compared to the control non-treated group that may assess its safety in liver and kidney tissues. Treatment of the rat model revealed a dose-dependent manner of effects that ranged from the mild expression of Bax in euphorbia extract at a low dose to moderate in a higher dose. Meanwhile, the reverse effect recorded for Bcl-2 immunostaining ranged from the moderate expression of Bcl-2 in low doses to mild expression in the higher dose in the cytoplasm of hepatocytes and glomeruli and renal tubules. That is except in the case of kidney tissue as regards Bcl-2 immunostaining in glomeruli and renal tubules which showed more precious effects ranging from the strong expression of Bcl-2 in euphorbia extract low-dose treated group to moderate in the higher dose-treated one. The present study results are consistent with those for many other anti-fibrotic agents that have inhibit apoptosis by upregulating Bcl-2 and downregulating Bax signaling, which is in a dose-dependent manner. A previous study used Ginkgo biloba extract, as a hepatoprotective from CCl4 liver fibrosis indicated from the immunohistochemistry analysis that the extract reduced liver fibrosis by mechanisms that may be associated with inhibiting hepatocyte apoptosis via downregulation of Bax, upregulation of Bcl-2 [35]. That is as in the case of salvianolic acids, which are the main active water-soluble extracts of *Salvia miltiorrhiza* Bunge. Salvianolic acids were suggested previously to be considered as a potential novel therapeutic agent for the treatment of fibrotic lung diseases and its antiapoptotic activity is represented via Bcl-2 protein decrease in a dose-dependent manner [36] and has previously been demonstrated to block hepatic fibrosis [37]. Also, arsenic trioxide was used on rat experimental hepatocellular carcinoma by DENA and its renal cytotoxicity was studied and recorded that arsenic trioxide didn't show obvious renal toxicity, and that was related to the increased expression of bcl-2 in the renal tubular epithelium, the inhibition of apoptosis and the anti-oxidation effects [38]. Several studies showed that renal toxicity had a close correlation with its oxidized damage to tubules and Bcl-2 is an apoptosis inhibitor and a strong anti-oxidant [39-42]. Inhibition of cell apoptosis via inhibition of Bax molecule expression and increase of Bcl-2 expression is suggested to delay or reverse renal tubular interstitial fibrosis, thus improving the renal function in kidney diseases [43, 44]. A previous study interested in the anti-proliferation activity of *Astragalus* treatment which is an extract from *Radix astragali* herbal plant on human HCC was recorded a significant decrease in the expression of anti-apoptotic protein Bcl-2 as compared with the control and the expression of the pro-apoptotic protein Bax was increased significantly by in a dose-dependent manner [45]. The results of the present study are in line with previous studies in stating that Bcl-2 and Bax function as tumor anti-apoptotic and pro-apoptotic factors that might interact with each other in regulating apoptosis and alteration of their levels influence apoptosis. Hence, the immunohistochemical results. Conclusion: The present study suggests that *E. inarticulata* Schweinf methanolic extract oral supplementation could protect the hepatorenal apoptosis in the HCC induced rat model by DENA and CCl4 via downregulation of the Bax and Bcl-2 protein expressions.

## Conclusion

This paper is interested in studying the immunohistochemical evaluation of *Euphorbia* extract on liver and kidney tissues in mice with liver cancer. TDENA/CCl4 rat model group showed an induced strong positive reaction to Bax immunostaining in the cytoplasm of liver cells and glomeruli and renal tubules, also they were treated with the *E. inarticulate* methanol extract recorded in photomicrograph (E) that the low dose of 250mg showed mild expression of Bax in glomeruli, while the high dose of 400mg showed moderate expression of Bax in the glomeruli and renal tubules (F). And we still need many studies in this field, and therefore the optimal use.

**Acknowledgments:** None

**Conflict of interest:** None

**Financial support:** None

**Ethics statement:** None

## References

1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1736-88.
2. Balogh J, Victor III D, Asham EH, Burroughs SG, Bektour M, Saharia A, et al. Hepatocellular carcinoma: a review. *J Hepatocell Carcinoma*. 2016;3:41.
3. Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. *Curr Chem Genom Transl Med*. 2018;12:9.
4. Lange N, Dufour JF. Changing epidemiology of HCC: how to screen and identify patients at risk?. *Dig Dis Sci*. 2019;64(4):903-9.
5. Bazarbashi S, Al Eid H, Minguet J. Cancer incidence in Saudi Arabia: 2012 data from the Saudi cancer registry. *Asian Pac J Cancer Prev*. 2017;18(9):2437.

6. Althubiti MA, Eldein MM. Trends in the incidence and mortality of cancer in Saudi Arabia. *Saudi Med J*. 2018;39(12):1259.
7. Dorsey BL, Haevermans T, Aubriot X, Morawetz JJ, Riina R, Steinmann VW, et al. Phylogenetics, morphological evolution, and classification of *Euphorbia* subgenus *Euphorbia*. *Taxon*. 2013;62(2):291-315.
8. Al-Sultan SI, Yehia AH. Acute toxicity of *Euphorbia helioscopia* in rats. *Pak J Nutr*. 2006;5:135-40.
9. Abebe W. An overview of Ethiopian traditional medicinal plants used for cancer treatment. *Eur J Med Plants*. 2016;14(4):1-16.
10. Alanzi A, Assiri A, Aldayel F, Allam A, Bin-Bakheet O, Alanzi F, et al. Herbal medicine among Saudis: awareness, uses, reasons and common herbs. *Int J Res Med Sci*. 2016;1(2):13-9.
11. Abu-Darwish MS, Effertth T. Medicinal plants from near east for cancer therapy. *Front Pharmacol*. 2018;9:56.
12. Tounekti T, Mahdhi M, Khemira H. Ethnobotanical study of indigenous medicinal plants of Jazan region, Saudi Arabia. *Evid-Based Complement Alternat Med*. 2019;2019.
13. Abulafatih HA. Medicinal plants in southwestern Saudi Arabia. *Econ Bot*. 1987;41(3):354-60.
14. Al-Farhan A, Al-Turki TA, Basahy RA. Flora of Jizan region, final report of project AR-17-7. King Abdulaziz City for Science and Technology (KACST), KSA. 2005;1:1-545.
15. Thomas J, El-Sheikh MA, Alfarhan AH, Alatar AA, Sivadasan M, Basahi M, et al. Impact of alien invasive species on habitats and species richness in Saudi Arabia. *J Arid Environ*. 2016;127:53-65.
16. Fayed AA, Al-Zahrani DA. Three new spiny *Euphorbia* (*Euphorbiaceae*) species from western Saudi Arabia. *Edinb J Bot*. 2007;64(2):117-29.
17. Ahmed S, Yousaf M, Mothana RA, Al-Rehaily AJ. Studies on wound healing activity of some *Euphorbia* species on experimental rats. *Afr J Tradit Complement Altern Med*. 2016;13(5):145-52.
18. Al-Hajj MM, Al-Shamahy HA, Alkhatib BY, Moharram BA. In vitro anti-leishmanial activity against cutaneous *Leishmania* parasites and preliminary phytochemical analysis of four Yemeni medicinal plants. *Universal J Pharm Res*. 2018;3:48-54.
19. Wang ZY, Liu HP, Zhang YC, Guo LQ, Li ZX, Shi XF. Anticancer potential of *Euphorbia helioscopia* L extracts against human cancer cells. *Anat Rec*. 2012;295(2):223-33.
20. Aly MS, Galaly SR, Moustafa N, Mohammed HM, Khadrawy SM, Mahmoud AM. Hesperidin protects against diethylnitrosamine/carbon tetrachloride-induced renal repercussions via up-regulation of Nrf2/HO-1 signaling and attenuation of oxidative stress. *J Appl Pharm Sci*. 2017;7(11):7-14.
21. Shalaby RH. Bcl-2 and Bax messenger RNA Gene expression detected by reverse transcriptase polymerase chain reaction after partial hepatectomy and licorice in rats. *Cytologia*. 2007;72(2):119-30.
22. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue—a review. *Diagn Pathol*. 2014;9(1):1-2.
23. Li Y, Martin RC. Herbal medicine and hepatocellular carcinoma: applications and challenges. *Evid Based Complement Alternat Med*. 2011;2011.
24. Abdel-Hamid NM, Abass SA, Mohamed AA, Hamid DM. Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors. *Biomed Pharmacother*. 2018;107:1246-58.
25. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. *J Hepatol*. 2002;37(1):22-30.
26. Huang X, Wang L, Meng M, Zhang S, Pham TT, Jiang L, et al. Extract of *Averrhoacarambola* L.(*Oxalidaceae*) roots ameliorates carbon tetrachloride-induced hepatic fibrosis in rats. *Biomed Pharmacother*. 2020;121:109516.
27. Tirkey N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. *BMC Pharmacol*. 2005;5(1):1-8.
28. Khan MR, Rizvi W, Khan GN, Khan RA, Shaheen S. Carbon tetrachloride-induced nephrotoxicity in rats: Protective role of *Digera muricata*. *J Ethnopharmacol*. 2009;122(1):91-9.
29. Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, Al-Shabanah OA, Abuhashish HM, Ahmed MM, et al. Protective effect of rutin on the antioxidant genes expression in hypercholesterolemic male Westar rat. *BMC Complement Altern Med*. 2013;13(1):1-9.
30. Bellassoued K, Ben Hsouna A, Athmouni K, van Pelt J, Makni Ayadi F, Rebai T, et al. Protective effects of *Mentha piperita* L. leaf essential oil against CCl4 induced hepatic oxidative damage and renal failure in rats. *Lipids Health Dis*. 2018;17(1):1-4.
31. Elguindy NM, Yacout GA, El Azab EF. Amelioration of DENA-induced oxidative stress in rat kidney and brain by the essential oil of *Elettaria cardamomum*. *Beni Suef Univ J Basic Appl Sci*. 2018;7(3):299-305.
32. Elsayy H, Badr GM, Sedky A, Abdallah BM, Alzahrani AM, Abdel-Moneim AM. Rutin ameliorates carbon tetrachloride (CCl4)-induced hepatorenal toxicity and hypogonadism in male rats. *Peer J*. 2019;7:e7011.
33. Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. *Curr Protoc Pharmacol*. 2014;66(1):14-30.
34. Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. *Mol Cell Biochem*. 2013;377(1):163-76.

35. Wang Y, Wang R, Wang Y, Peng R, Wu Y, Yuan Y. Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF- $\kappa$ B/I $\kappa$ B $\alpha$ , and Bcl-2/Bax signaling. *Drug Des Devel Ther.* 2015;9:6303.
36. Pan Y, Fu H, Kong Q, Xiao Y, Shou Q, Chen H, et al. Prevention of pulmonary fibrosis with salvianolic acid by inducing fibroblast cell cycle arrest and promoting apoptosis. *J Ethnopharmacol.* 2014;155(3):1589-96.
37. Tsai MK, Lin YL, Huang YT. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. *Toxicol Appl Pharmacol.* 2010;242(2):155-64.
38. Wang SS, Zhang T, Wang XL, Hong L, Qi QH. Effect of arsenic trioxide on rat hepatocarcinoma and its renal cytotoxicity. *World J Gastroenterol.* 2003;9(5):930.
39. Jiang Y, Zhou XD, Liu YK, Wu X, Huang XW. Association of hTcf-4 gene expression and mutation with clinicopathological characteristics of hepatocellular carcinoma. *World J Gastroenterol.* 2002;8(5):804.
40. Yang LJ, Wang WL. Preparation of monoclonal antibody against apoptosis-associated antigens of hepatoma cells by subtractive immunization. *World J Gastroenterol.* 2002;8(5):808.
41. Huang GW, Yang LY. Metallothionein expression in hepatocellular carcinoma. *World J Gastroenterol.* 2002;8(4):650.
42. Huang J, Cai MY, Wei DP. HLA class I expression in primary hepatocellular carcinoma. *World J Gastroenterol.* 2002;8(4):654.
43. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. *Am J Physiol Renal Physiol.* 2006;290(1):F4-13.
44. Zhang QF. Ulinastatin inhibits renal tubular epithelial apoptosis and interstitial fibrosis in rats with unilateral ureteral obstruction. *Mol Med Rep.* 2017;16(6):8916-22.
45. Li LK, Kuang WJ, Huang YF, Xie HH, Chen G, Zhou QC, et al. Anti-tumor effects of Astragalus on hepatocellular carcinoma in vivo. *Indian J Pharmacol.* 2012;44(1):78.